FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137609052> ?p ?o ?g. }

• W3137609052 endingPage "S285" @default.
• W3137609052 startingPage "S284" @default.
• W3137609052 abstract "PurposeHypertension after heart transplantation (HTx) is noted in a majority of HTx patients due to the side effects of calcineurin inhibitors (CNI). The use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are effective anti-hypertensive agents and may have longer term clinical benefits. We assessed our patients on ACEI/ARBs versus others in the first year post-HTx and followed them for 5-year outcomes.MethodsBetween 2010 and 2015, we assessed 101 HTx patients who were on ACEI/ARBs only in the first year for more than 6 months. Those patients were then followed for 5 years. Likewise, a group of patients who were placed on non-ACEI/ARBs blood pressure medications, such as calcium channel-blockers, beta blockers, and diuretics, in the first year for more than 6 months were the control group. Outcomes included 5-year survival, 5-year freedom from non-fatal major adverse cardiac event (NF-MACE: MI, new CHF, PCI, ICD implant, stroke), freedom from cardiac allograft vasculopathy (CAV: angiographic stenosis >30%), freedom from left ventricular dysfunction (left ventricular ejection fraction ≤40%) and freedom from left ventricular hypertrophy (LVH), defined as intraventricular septum or posterior wall ≥1.3cm.ResultsThe patients treated with ACEI/ARBs in the first year post-HTx compared to those without had significantly lower 5-year survival but a trend for greater 5-year freedom from CAV. There was no significant difference between the two study groups in 5-year freedom from NF-MACE, left ventricular dysfunction and LVH (see table). Baseline demographics between groups were similar for recipient age, % female, pre-transplant diabetes and renal dysfunction (creatinine >1.5mg/dl) (data not shown).ConclusionThe use of ACEI/ARBs in the first year post-HTx is associated with lower survival but other factors may be involved. A possible lower development of CAV from ACEI/ARBs may be a benefit to be explored. Hypertension after heart transplantation (HTx) is noted in a majority of HTx patients due to the side effects of calcineurin inhibitors (CNI). The use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) are effective anti-hypertensive agents and may have longer term clinical benefits. We assessed our patients on ACEI/ARBs versus others in the first year post-HTx and followed them for 5-year outcomes. Between 2010 and 2015, we assessed 101 HTx patients who were on ACEI/ARBs only in the first year for more than 6 months. Those patients were then followed for 5 years. Likewise, a group of patients who were placed on non-ACEI/ARBs blood pressure medications, such as calcium channel-blockers, beta blockers, and diuretics, in the first year for more than 6 months were the control group. Outcomes included 5-year survival, 5-year freedom from non-fatal major adverse cardiac event (NF-MACE: MI, new CHF, PCI, ICD implant, stroke), freedom from cardiac allograft vasculopathy (CAV: angiographic stenosis >30%), freedom from left ventricular dysfunction (left ventricular ejection fraction ≤40%) and freedom from left ventricular hypertrophy (LVH), defined as intraventricular septum or posterior wall ≥1.3cm. The patients treated with ACEI/ARBs in the first year post-HTx compared to those without had significantly lower 5-year survival but a trend for greater 5-year freedom from CAV. There was no significant difference between the two study groups in 5-year freedom from NF-MACE, left ventricular dysfunction and LVH (see table). Baseline demographics between groups were similar for recipient age, % female, pre-transplant diabetes and renal dysfunction (creatinine >1.5mg/dl) (data not shown). The use of ACEI/ARBs in the first year post-HTx is associated with lower survival but other factors may be involved. A possible lower development of CAV from ACEI/ARBs may be a benefit to be explored." @default.
• W3137609052 created "2021-03-29" @default.
• W3137609052 creator A5020746104 @default.
• W3137609052 creator A5021735902 @default.
• W3137609052 creator A5031986645 @default.
• W3137609052 creator A5034147901 @default.
• W3137609052 creator A5046477718 @default.
• W3137609052 creator A5057486633 @default.
• W3137609052 creator A5062387574 @default.
• W3137609052 creator A5065002546 @default.
• W3137609052 creator A5068372296 @default.
• W3137609052 creator A5083295306 @default.
• W3137609052 creator A5091270315 @default.
• W3137609052 date "2021-04-01" @default.
• W3137609052 modified "2023-09-27" @default.
• W3137609052 title "The Clinical Impact of ACEI/ARBs in Heart Transplantation: Perhaps Not All Good" @default.
• W3137609052 doi "https://doi.org/10.1016/j.healun.2021.01.808" @default.
• W3137609052 hasPublicationYear "2021" @default.
• W3137609052 type Work @default.
• W3137609052 sameAs 3137609052 @default.
• W3137609052 citedByCount "0" @default.
• W3137609052 crossrefType "journal-article" @default.
• W3137609052 hasAuthorship W3137609052A5020746104 @default.
• W3137609052 hasAuthorship W3137609052A5021735902 @default.
• W3137609052 hasAuthorship W3137609052A5031986645 @default.
• W3137609052 hasAuthorship W3137609052A5034147901 @default.
• W3137609052 hasAuthorship W3137609052A5046477718 @default.
• W3137609052 hasAuthorship W3137609052A5057486633 @default.
• W3137609052 hasAuthorship W3137609052A5062387574 @default.
• W3137609052 hasAuthorship W3137609052A5065002546 @default.
• W3137609052 hasAuthorship W3137609052A5068372296 @default.
• W3137609052 hasAuthorship W3137609052A5083295306 @default.
• W3137609052 hasAuthorship W3137609052A5091270315 @default.
• W3137609052 hasBestOaLocation W31376090521 @default.
• W3137609052 hasConcept C126322002 @default.
• W3137609052 hasConcept C127413603 @default.
• W3137609052 hasConcept C128057223 @default.
• W3137609052 hasConcept C164705383 @default.
• W3137609052 hasConcept C2776002628 @default.
• W3137609052 hasConcept C2778198053 @default.
• W3137609052 hasConcept C2778849806 @default.
• W3137609052 hasConcept C2780645631 @default.
• W3137609052 hasConcept C2780739214 @default.
• W3137609052 hasConcept C2911091166 @default.
• W3137609052 hasConcept C45393284 @default.
• W3137609052 hasConcept C500558357 @default.
• W3137609052 hasConcept C71924100 @default.
• W3137609052 hasConcept C78085059 @default.
• W3137609052 hasConcept C78519656 @default.
• W3137609052 hasConcept C84393581 @default.
• W3137609052 hasConceptScore W3137609052C126322002 @default.
• W3137609052 hasConceptScore W3137609052C127413603 @default.
• W3137609052 hasConceptScore W3137609052C128057223 @default.
• W3137609052 hasConceptScore W3137609052C164705383 @default.
• W3137609052 hasConceptScore W3137609052C2776002628 @default.
• W3137609052 hasConceptScore W3137609052C2778198053 @default.
• W3137609052 hasConceptScore W3137609052C2778849806 @default.
• W3137609052 hasConceptScore W3137609052C2780645631 @default.
• W3137609052 hasConceptScore W3137609052C2780739214 @default.
• W3137609052 hasConceptScore W3137609052C2911091166 @default.
• W3137609052 hasConceptScore W3137609052C45393284 @default.
• W3137609052 hasConceptScore W3137609052C500558357 @default.
• W3137609052 hasConceptScore W3137609052C71924100 @default.
• W3137609052 hasConceptScore W3137609052C78085059 @default.
• W3137609052 hasConceptScore W3137609052C78519656 @default.
• W3137609052 hasConceptScore W3137609052C84393581 @default.
• W3137609052 hasIssue "4" @default.
• W3137609052 hasLocation W31376090521 @default.
• W3137609052 hasOpenAccess W3137609052 @default.
• W3137609052 hasPrimaryLocation W31376090521 @default.
• W3137609052 hasRelatedWork W2316342240 @default.
• W3137609052 hasRelatedWork W2407717929 @default.
• W3137609052 hasRelatedWork W2922135971 @default.
• W3137609052 hasRelatedWork W3033076790 @default.
• W3137609052 hasRelatedWork W3095613549 @default.
• W3137609052 hasRelatedWork W3155674270 @default.
• W3137609052 hasRelatedWork W3159201697 @default.
• W3137609052 hasRelatedWork W3210028768 @default.
• W3137609052 hasRelatedWork W4200030969 @default.
• W3137609052 hasRelatedWork W4249414561 @default.
• W3137609052 hasVolume "40" @default.
• W3137609052 isParatext "false" @default.
• W3137609052 isRetracted "false" @default.
• W3137609052 magId "3137609052" @default.
• W3137609052 workType "article" @default.